Literature DB >> 11561980

The relationships between the HIV test interval, demographic factors and HIV disease progression.

.   

Abstract

Individuals developing an HIV seroconversion illness may experience rapid disease progression. Information on seroconversion illness is rarely collected in most cohort studies, thus the aim of this study was to assess the value of the HIV test interval (the time between last negative and first positive HIV tests) as a proxy for seroconversion illness. Among 8229 seroconverters, test intervals ranged from 0-5282 days, and varied by gender, risk group, age and calendar year of seroconversion. Those with intervals < or = 31 days had an increased hazard of AIDS (RH 1.42, P = 0.07), which was reduced slightly after adjusting for baseline factors, calendar year of follow-up, treatment and the declining CD4 count, but there was no effect on survival. Thus, it appears that if information on acute seroconversion illness is not available, then analyses of progression to AIDS in seroconverter studies could use a short test interval as a proxy measure.

Entities:  

Mesh:

Year:  2001        PMID: 11561980      PMCID: PMC2869734          DOI: 10.1017/s0950268801005805

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  3 in total

1.  Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks.

Authors:  Abdel Babiker; Janet Darbyshire; Patrizio Pezzotti; Kholoud Porter; Giovanni Rezza; Sarah A Walker; Valerie Beral; Roel Coutinho; Julia Del Amo; Noël Gill; Christine Lee; Laurence Meyer; Freya Tyrer; Francois Dabis; Rodolphe Thiebaut; Sylvie Lawson-Aye; Faroudy Boufassa; Osamah Hamouda; Klaus Fischer; Patrizio Pezzotti; Giovanni Rezza; Giota Touloumi; Angelos Hatzakis; Anastasia Karafoulidou; Olga Katsarou; Ray Brettle; Jorge del Romero; Maria Prins; Birgit van Benthem; Ole Kirk; Court Pederson; Idelfonso Hernández Aguado; Santiago Pérez-Hoyos; Anne Eskild; Johan N Bruun; Mette Sannes; Caroline Sabin; Christine Lee; Anne M Johnson; Andrew N Phillips; Patrick Francioli; Philippe Vanhems; Mathias Egger; Martin Rickenbach; David Cooper; John Kaldor; Lesley Ashton; Jeanette Vizzard; Roberto Muga; Nicholas E Day; Daniela De Angelis
Journal:  Int J Epidemiol       Date:  2002-10       Impact factor: 7.196

2.  Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection.

Authors:  Sara Lodi; Martin Fisher; Andrew Phillips; Andrea De Luca; Jade Ghosn; Ruslan Malyuta; Robert Zangerle; Santiago Moreno; Philippe Vanhems; Faroudy Boufassa; Marguerite Guiguet; Kholoud Porter
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

3.  Evaluation of rapid progressors in HIV infection as an extreme phenotype.

Authors:  Ashley D Olson; Marguerite Guiguet; Robert Zangerle; John Gill; Santiago Perez-Hoyos; Sara Lodi; Jade Ghosn; Maria Dorrucci; Anne Johnson; Mette Sannes; Santiago Moreno; Kholoud Porter
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.